Related Experiment Video
Updated: Feb 27, 2026

Electroactive Polymer Nanoparticles Exhibiting Photothermal Properties
Published on: January 8, 2016
Zeta potential changing self-emulsifying drug delivery systems containing phosphorylated polysaccharides
Janine Griesser1, Stephanie Burtscher1, Saskia Köllner1
1Thiomatrix Forschungs-und Beratungs GmbH, Trientlgasse 65, Innsbruck, Austria.
Aim:
The aim of the study was to develop novel zeta potential changing self-emulsifying drug delivery systems (SEDDS) containing phosphorylated polysaccharides.
Methods:
Starch and hydroxypropyl starch (HPS) were phosphorylated by utilizing phosphorus pentoxide. The modified starches, starch phosphate (SP) and hydroxypropyl starch phosphate (HPSP), were loaded into SEDDS and investigated regarding particle size, zeta potential, stability and cell viability. The release of immobilized phosphate by intestinal alkaline phosphatase (IAP) was analyzed via malachite green assay. In parallel, the resulting shift in zeta potential of SEDDS was determined. Furthermore, Transwell chambers were applied in order to evaluate the mucus diffusion behavior of SEDDS utilizing fluorescein diacetate (FDA) as marker.
Results:
The amount of attached phosphate for SP and HPSP revealed to be 119μmol/g and 259μmol/g, respectively. SEDDS consisting of 10% glycerol, 30% Capmul MCM, 30% Cremophor EL and 30% Captex 355 showed a droplet size of 39±12nm, stability over 240min and no significant decrease in cell viability within the applied concentrations. SEDDS containing 3mg/ml HPSP with a phosphate release of 204μmol/g, demonstrated a shift in zeta potential from -6.3mV to +1.0mV applying isolated IAP. Zeta potential changing SEDDS achieved a 2.5-fold and 5.4-fold higher amount of diffused FDA compared to the references within mucus permeation studies.
Conclusion:
SEDDS containing HPSP represent comparable high mucus diffusion properties emphasized by a highly significant change in zeta potential.
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Stimuli-Activated
Modified-Release Drug Delivery Systems: Rate-Programmed II
Modified-Release Drug Delivery Systems: Rate-Programmed I
Modified-Release Drug Delivery Systems: Classification
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

